Silence Therapeutics (SLN) Retained Earnings (2019 - 2025)
Silence Therapeutics (SLN) has disclosed Retained Earnings for 7 consecutive years, with -$3.0 million as the latest value for Q4 2025.
- Quarterly Retained Earnings rose 99.37% to -$3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.0 million through Dec 2025, up 99.37% year-over-year, with the annual reading at -$3.0 million for FY2025, 99.37% up from the prior year.
- Retained Earnings hit -$3.0 million in Q4 2025 for Silence Therapeutics, up from -$550.8 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$3.0 million in Q4 2025 to a low of -$550.8 million in Q3 2025.
- Historically, Retained Earnings has averaged -$380.9 million across 5 years, with a median of -$426.1 million in 2023.
- Biggest five-year swings in Retained Earnings: decreased 25.39% in 2024 and later soared 99.37% in 2025.
- Year by year, Retained Earnings stood at -$300.6 million in 2021, then fell by 2.74% to -$308.8 million in 2022, then decreased by 22.44% to -$378.1 million in 2023, then fell by 25.39% to -$474.0 million in 2024, then skyrocketed by 99.37% to -$3.0 million in 2025.
- Business Quant data shows Retained Earnings for SLN at -$3.0 million in Q4 2025, -$550.8 million in Q3 2025, and -$529.8 million in Q2 2025.